Sansure Biotech Inc. (SHA: 688289) announced that its Nucleic Acid Detection Kit for Parainfluenza Virus, Human Rhinovirus, Adenovirus and Mycoplasma pneumoniae (Fluorescent PCR Method) has received a Medical Device Registration Certificate from China’s National Medical Products Administration (NMPA), marking the company’s second lyophilized quadruplex detection product following the approval of its first four‑in‑one panel covering SARS‑CoV‑2, influenza A, influenza B and respiratory syncytial virus (RSV).
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Action | Medical Device Registration Certificate issued |
| Registrant | Sansure Biotech Inc. (SHA: 688289) |
| Product | Nucleic Acid Detection Kit for Parainfluenza Virus, Human Rhinovirus, Adenovirus and Mycoplasma pneumoniae (Fluorescent PCR Method) |
| Intended Use | In vitro qualitative detection of nucleic acids of parainfluenza virus (types 1, 2, 3), human rhinovirus, adenovirus and Mycoplasma pneumoniae in human pharyngeal swab specimens |
| Registration No. | 国械注准 20263402137 |
| Classification | Domestic Class III in vitro diagnostic reagent |
| Certificate Validity | Through 8 Oct 2031 |
Product Profile & Technology
- Dual Quadruplex Layout: The newly approved kit is the second lyophilized four‑in‑one product from Sansure, complementing its first approved quadruplex panel (SARS‑CoV‑2 / influenza A / influenza B / RSV). Through differentiated pathogen combinations, the two products deliver complementary coverage of 8 common respiratory pathogens, completing Sansure’s respiratory infection pathogen detection matrix.
- AI‑Driven Enzyme Evolution: Both quadruplex products are built on Sansure’s AI‑driven enzyme evolution technology – artificial‑intelligence‑assisted protein design and optimization that significantly enhances enzyme performance, underpinning lyophilized reagent stability, detection efficiency and product standardization.
- Lyophilized Format: The freeze‑dried chemistry preserves the “rapid, multi‑target, simple operation, cold‑chain‑free” technology advantages – critical for deployment beyond centralized laboratories.
- Platform Compatibility: The kit is compatible with both Sansure’s molecular POCT (Point‑of‑Care Testing) platform and conventional PCR testing platforms, balancing detection efficiency, operational convenience and application flexibility across diverse healthcare settings.
Clinical & Commercial Positioning
- Flexible Pathogen Differentiation: The expanded matrix offers clinicians more flexible and efficient pathogen identification schemes for respiratory infections – including atypical pathogens such as Mycoplasma pneumoniae and frequently co‑circulating viruses such as rhinovirus and adenovirus.
- Tiered Diagnostic Solutions: Sansure is building layered detection solutions covering multiple common respiratory pathogens to meet diverse clinical needs across different tiers of medical institutions and multiple clinical scenarios.
- Innovation Engine: The portfolio is powered by the convergence of AI protein‑evolution enzyme technology, lyophilized nucleic acid detection technology and the rapid molecular POCT platform – a triad that supports both performance and scalability.
- Respiratory Season Timing: Registration ahead of the winter respiratory season positions the two quadruplex panels for near‑term clinical adoption in hospitals, primary care and POCT settings.
Market Impact & Outlook
- Eight‑Pathogen Complementary Coverage: The dual quadruplex strategy transforms Sansure’s respiratory menu from single panels into an integrated 8‑pathogen differential diagnostic ecosystem, strengthening its competitiveness in China’s large and fast‑growing respiratory molecular diagnostics market.
- Cold‑Chain‑Free Advantage: Lyophilized, cold‑chain‑independent reagents lower logistics barriers for primary‑level medical institutions – a decisive factor in China’s tiered healthcare market and in export opportunities.
- AI‑Enabled Manufacturing Differentiation: AI‑assisted enzyme design delivers measurable gains in reagent stability and standardization, giving Sansure a technology moat in multiplex PCR chemistry development.
- POCT Growth Vector: Compatibility with the molecular POCT platform aligns the quadruplex products with the shift toward decentralized, near‑patient respiratory testing.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization, market adoption and product pipeline development of Sansure Biotech’s respiratory diagnostic products. Actual results may differ materially due to risks including procurement and reimbursement policies, competitive dynamics in molecular diagnostics, and product performance in real‑world clinical use.-Fineline Info & Tech
